IP Library Granted Patent US 10,004,714
Granted Patent B2
US 10,004,714 · App. 14/414,030 · Granted Jun 26, 2018

Compositions, methods and/or devices for prevention and/or treatment of dry eye disorders

Inventors: Hua Zhu (Bexley, AU); Judith Louise Flanagan (Newtown, AU)
Assignee: Brien Holden Vision Institute
A61K31/23A61K9/0048A61K31/20A61K31/202A61K31/568A61K31/5685A61K31/7052A61K38/13A61K38/1841A61K45/06A61K47/06A61K47/24A61K47/44A61L12/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,004,714
App. No.
14/414,030
Granted
Jun 26, 2018
Kind
B2
Abstract

The present disclosure relates to compositions, methods and devices for treating, reducing or preventing one or more eye disorders, particularly dry eye disorders, in a subject by administering an amount of one or more fatty acids and/or fatty acid esters therapeutically effective to inhibit lipase activity while permitting bacterial growth or without substantially altering the dynamic microbial community of the eye. Typically, the fatty acids and/or fatty acid esters are C 8 to C 16 fatty acids and/or fatty acid esters.

Claims (7)

1. A method for treating a dry eye disorder in a subject by administering to the subject's eye a composition with an amount of lauric acid or a combination of lauric acid and glycerol monolaurate therapeutically effective to inhibit lipase activity by about 35% to 75% without substantially altering the dynamic microbial community of the subject's eye to which the composition has been administered;

wherein the amount of lauric acid or a combination of lauric acid and glycerol monolaurate is in a concentration of between 2.5 μg/ml to 15 μg/ml in the composition.

2. A method according to claim 1 , wherein the topical administration is in the form of an ointment, cream, eye drops or released from an ophthalmic device.

3. The method of claim 2 , wherein the composition is released from the ophthalmic device and the ophthalmic device is a contact lens.

4. The method of claim 2 , wherein the concentration of lauric acid or a combination of lauric acid and glycerol monolaurate is 2.5 μg/ml to 15 μg/ml in the eye drops administered to the eye.

5. The method of claim 2 , wherein the concentration of lauric acid or a combination of lauric acid and glycerol monolaurate is 2.5 μg/ml to 15 μg/ml in a composition associated with a contact lens.

6. The method according to claim 1 , wherein the amount of lauric acid or a combination of lauric acid and glycerol monolaurate is therapeutically effective to inhibit lipase activity in the subject's eye while permitting bacterial growth in the subject's eye.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2015
From: ZHU, HUA; FLANAGAN, JUDITH LOUISE
To: BRIEN HOLDEN VISION INSTITUTE
Reel/Frame 034676/0422 →
Priority Claims (1)
AU 2012902937 · Jul 9, 2012 · national
Continuity (1)
Related Publication 20150157591A1 · Jun 11, 2015
Cited By (3)
US 12,419,933 US 12,496,326 US 12,569,452